Adult T-cell leukemia/lymphoma and HTLV-1

被引:34
作者
Mahieux R. [1 ]
Gessain A. [1 ]
机构
[1] CNRS URA 3015, Department of Virology, Institut Pasteur, 75724 Paris Cedex 15
关键词
Alemtuzumab; Arsenic Trioxide; Proviral Load; ATLL Cell; ATLL Patient;
D O I
10.1007/s11899-007-0035-x
中图分类号
学科分类号
摘要
Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) was the first oncogenic human retrovirus to be discovered, more than 25 years ago. HTLV-1 infects 15 to 20 million individuals worldwide. This oncoretrovirus can be transmitted in three ways: horizontally (sexually), vertically (mother to child), and via blood transfusion. HTLV-1 causes two major diseases: adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1- associated myelopathy (TSP/HAM). ATLL can be classified into four major subtypes: a smoldering type, a chronic type, a lymphoma type, and a leukemic type. Because of intrinsic chemoresistance and severe immunosuppression, the survival rate of ATLL patients, especially those who develop the acute leukemic or lymphoma forms, is very poor, and such clonal malignant CD4 expansion remains one of the most severe lymphoproliferations. This article discusses a number of recent treatments including antiretroviral therapy, aggressive chemotherapy, and allogeneic bone-marrow transplantation, as well as new drugs. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:257 / 264
页数:7
相关论文
共 55 条
[31]  
Gabet A.S., Mortreux F., Talarmin A., Et al., High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis, Oncogene, 19, pp. 4954-4960, (2000)
[32]  
Afonso P.V., Zamborlini A., Saib A., Mahieux R., Centrosome and retroviruses: The dangerous liaisons [review], Retrovirology, 4, (2007)
[33]  
Hanon E., Hall S., Taylor G.P., Et al., Abundant Tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes, Blood, 95, pp. 1386-1392, (2000)
[34]  
Hanon E., Stinchcombe J.C., Saito M., Et al., Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I, Immunity, 13, pp. 657-664, (2000)
[35]  
Gaudray G., Gachon F., Basbous J., Et al., The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription, J Virol, 76, pp. 12813-12822, (2002)
[36]  
Bazarbachi A., Ghez D., Lepelletier Y., Et al., New therapeutic approaches for adult T-cell leukaemia, Lancet Oncol, 5, pp. 664-672, (2004)
[37]  
Tsukasaki K., Utsunomiya A., Fukuda H., Et al., Clinical trials for the treatment of ATLL by the Japan Clinical Oncology Group (JCOG) [abstract], AIDS Res Hum Retroviruses, 23, pp. 592-593, (2007)
[38]  
Hermine O., Panelatti G., Ramos J., Et al., A worldwide meta-analysis of the use of zidovudine and interferon alpha for the treatment of adult T-cell leukemia/lymphoma [abstract], AIDS Res Hum Retroviruses, 23, pp. 597-598, (2007)
[39]  
Ramos J.C., Ruiz Jr P., Ratner L., Et al., IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma, Blood, 109, pp. 3060-3068, (2007)
[40]  
Jeang K.T., Giam C.Z., Majone F., Aboud M., Life, death, and Tax: Role of HTLV-I oncoprotein in genetic instability and cellular transformation, J Biol Chem, 279, pp. 31991-31994, (2004)